- Home
- AYTU vs CLDI Comparison
AYTU vs CLDI Comparison
Compare AYTU & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- CLDI
- Stock Information
- Founded
- AYTU N/A
- CLDI 2014
- Country
- AYTU United States
- CLDI United States
- Employees
- AYTU N/A
- CLDI N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AYTU Health Care
- CLDI Health Care
- Exchange
- AYTU Nasdaq
- CLDI Nasdaq
- Market Cap
- AYTU 9.6M
- CLDI 10.2M
- IPO Year
- AYTU N/A
- CLDI N/A
- Fundamental
- Price
- AYTU $2.21
- CLDI $0.23
- Analyst Decision
- AYTU Strong Buy
- CLDI Strong Buy
- Analyst Count
- AYTU 1
- CLDI 1
- Target Price
- AYTU $12.00
- CLDI $10.00
- AVG Volume (30 Days)
- AYTU 624.8K
- CLDI 1.8M
- Earning Date
- AYTU 05-14-2025
- CLDI 08-12-2025
- Dividend Yield
- AYTU N/A
- CLDI N/A
- EPS Growth
- AYTU N/A
- CLDI N/A
- EPS
- AYTU N/A
- CLDI N/A
- Revenue
- AYTU $81,659,000.00
- CLDI N/A
- Revenue This Year
- AYTU N/A
- CLDI N/A
- Revenue Next Year
- AYTU $8.68
- CLDI N/A
- P/E Ratio
- AYTU N/A
- CLDI N/A
- Revenue Growth
- AYTU 0.41
- CLDI N/A
- 52 Week Low
- AYTU $0.95
- CLDI $0.20
- 52 Week High
- AYTU $2.96
- CLDI $3.89
- Technical
- Relative Strength Index (RSI)
- AYTU 63.18
- CLDI 22.56
- Support Level
- AYTU $2.04
- CLDI $0.20
- Resistance Level
- AYTU $2.40
- CLDI $0.25
- Average True Range (ATR)
- AYTU 0.14
- CLDI 0.03
- MACD
- AYTU 0.00
- CLDI -0.00
- Stochastic Oscillator
- AYTU 54.90
- CLDI 14.20
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.